Authors
Latest:
Making Strides Against a Rare Disease: Renal Medullary Carcinoma in FocusRenal medullary carcinoma is a rare but devastating tumor type almost exclusively affecting young adults carrying 1 copy of hemoglobin beta (HBB) harboring the A17T mutation (HbS).
Latest:
Dr. Linehan on Treatment for Hereditary Leiomyomatosis and RCCW. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses the treatment of hereditary leiomyomatosis and renal cell cancer (HLRCC).
Latest:
Nodule Size Should Not Determine Biopsy Decision in Thyroid CancerThe recent American Thyroid Association guidelines to abstain from cytological evaluation by biopsy for patients with thyroid cancer on the basis of having thyroid nodules ≤1 cm is not advisable.
Latest:
Coexisting BRAF/TERT Mutations Predict Aggressive Thyroid CancerCoexisting mutations in BRAF and TERT may be associated with an aggressive phenotype and higher recurrence rates for patients with locally advanced well-differentiated thyroid cancers.
Latest:
Dr. Lai on the Results of the CASPIAN Trial in Small Cell Lung CancerW. Victoria Lai, MD, discusses the results of the phase III CASPIAN trial in small cell lung cancer.
Latest:
Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.
Latest:
Targeted Therapies and Biomarkers for SCLC: What’s Next on the HorizonPanelists discuss how emerging targeted and biomarker-directed therapies are poised to transform the treatment landscape for both limited-stage and extensive-stage small cell lung cancer, highlighting the potential for improved patient outcomes through personalized approaches.
Latest:
Dr. El-Deiry on Liquid Vs Tissue BiopsiesWafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses the advantages of liquid biopsies over tissue biopsies.
Latest:
It's Not Quite Prime Time for Up-Front Genomic Sequencing in Early-Stage CRCAlthough testing for some genetic defects has been incorporated into the treatment paradigm, the clinical utility of up-front tumor sequencing that would yield wide-ranging information has not yet been established.
Latest:
Dr. Akerley on MET Biomarker in Lung CancerWallace L. Akerley, MD, discusses using MET as a biomarker in lung cancer.
Latest:
Dr Curran on Developing Strategies for Stage III NSCLC ManagementWally Curran, MD, discusses current and developing treatment strategies for patients with stage III unresectable non–small cell lung cancer.
Latest:
Dr. Curran on the Integration of Immunotherapy With Radiation Therapy in Lung CancerWalter J. Curran, Jr, MD, FACR, FASCO, explains the eligibility criteria for immunotherapy and radiation in patients with lung cancer.
Latest:
Dr Stadler on Enhancing Diversity in Early Phase Clinical Trials For Underserved CommunitiesWalter M. Stadler, MD, discusses his role within the Stand Up To Cancer® 4-team initiative, where he will aim to enhance diversity in early-phase clinical trials in underserved urban community.
Latest:
Dr. Rayford on the Racial Genomics of Prostate CancerWalter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses the racial genomics of prostate cancer.
Latest:
Cervical Cancer Management: Looking Toward the Future of CareClosing out their discussion on the management of cervical cancer, panelists share their excitement for future evolutions in care.
Latest:
Dr. Abida on Future Research Directions in mCRPCWassim Abida, MD, PhD, discusses future research directions in the treatment of patients with metastatic castration-resistant prostate cancer.
Latest:
Dr. Hong on Advances in Head and Neck CancerWaun K. Hong, MD, FACP, DMSc, division head, American Cancer Society Professor, Samsung Distinguished University Chair in Cancer Medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, and 2018 Giant of Cancer Care® in Head and Neck Cancer, discusses advances in the treatment of patients with head and neck cancer.
Latest:
Dr. Bardwell Expresses the Importance of ListeningDr. Wayne Bardwell from UCSD Cancer Center Expresses the Importance of Listening
Latest:
Dr. Marasco on Engineering CAR T CellsWayne A. Marasco, MD, PhD, discusses ways CAR T cells are being engineered to avoid on-target adverse events in solid tumors.
Latest:
Lenalidomide/Rituximab Regimens Show Encouraging Responses in Relapsed/Refractory Follicular Lymphoma, But Slow Accrual Axes StudyThe regimen of lenalidomide in combination with rituximab with bendamustine are effective therapies for relapsed/refractory follicular lymphoma, with high rates of overall and complete metabolic response by PET, according to data from the randomized phase 2 HOVON110/Rebel trial.
Latest:
Dr. Ai on the FDA Approval of Mogamulizumab in CTCLWei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.
Latest:
Dr. Sun on the KEYNOTE-062 Design in Advanced Gastric/GEJ CancerWeijing Sun, MD, FACP, discusses the design of the KEYNOTE-062 trial in advanced gastric/gastroesophageal junction cancer.
Latest:
Dr. Ai on the Efficacy of Brentuximab Vedotin in Patients With Advanced CTCLWeiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, discusses the scenarios in which she has seen the most benefit from brentuximab vedotin (Adcetris) in patients with advanced stage cutaneous T-cell lymphoma.
Latest:
Dr. Tereffe on Treatment After Neoadjuvant Chemotherapy in Breast CancerWelela Tereffe, MD, associate professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses the role of radiation therapy in the treatment of patients with breast cancer who previously received neoadjuvant chemotherapy.
Latest:
Dr. Messersmith on the Potential for Trastuzumab Deruxtecan in HER2+ CRCWells Messersmith, MD, discusses the potential for fam-trastuzumab deruxtecan-nxki as a treatment for patients with HER2-positive colorectal cancer.
Latest:
New Frontier for Genomics: Radiotherapy in Early Breast CancerBy individualizing risk of locoregional recurrence and radiosensitivity with molecular subtyping/genomic classifiers, it is hoped that use and/or extent of adjuvant radiation therapy could be tailored in early-stage breast cancer.
